Search results
David Power
Job title: Interventional Cardiologist
Author
The Power of Storytelling: Lindsay's Big Heart and HCM Awareness
Added:
1 year ago
Podcast Episode
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes…
View more
Targeting Obesity for Heart Failure
Author(s):
Emily Morris
,
Oliver J Rider
Added:
2 months ago
Review Article
ESC 2023 – Heart Failure Guideline Review
Video Series
Author(s):
Milind Y Desai
Added:
6 months ago
ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.The ODYSSEY-HCM study was a…
View more
Author(s):
Gregory Lewis
Added:
4 months ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance…
View more
High TnI after OPCABG
Author(s):
Hao Cui
,
Jinwei Zhang
,
Jianbo Yu
,
et al
Added:
6 months ago
Original Research
Author(s):
Harriette Van Spall
,
James L Januzzi
Added:
1 year ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).This phase 3 multicenter, randomized,…
View more
Digisonics Inc
Author
